RxDoctor Payments DataLook up a doctor →

William Barajimenez, MD

Neurology · Kensington, MDNPI 1407931496

Payments from drug & device makers

$71,402in general payments, 2019–2025

Across 1,917 payments — averaging $37.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$36K
  • AbbVie$5K
  • Teva Pharmaceuticals USA, Inc.$3K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • UCB, Inc.$1K
  • plus $23K from 54 others

What the payments were for

  • Speaking & faculty fees$33,98948%
  • Travel & lodging$1,4252%
  • Food & beverage$34,54348%
  • Education$1,4442%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.75$36,301
AbbVie(2 entities)336$4,574
Teva Pharmaceuticals USA, Inc.94$2,521
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)98$1,898
Otsuka America Pharmaceutical, Inc.85$1,447
UCB, Inc.77$1,398
Lilly USA, LLC77$1,390
Lundbeck LLC71$1,350
Novartis86$1,304
Harmony Biosciences LLC43$1,303
Jazz Pharmaceuticals Inc.51$1,173
Kyowa Kirin, Inc.43$973
Eisai Inc.44$968
Pfizer50$921
Livanova USA, Inc.7$900
Biogen46$869
Acadia Pharmaceuticals Inc34$859
MDD US Operations, LLC27$814
Neurocrine Biosciences, Inc.44$780
Supernus Pharmaceuticals, Inc.45$773
ANI Pharmaceuticals, Inc.36$741
Axsome Therapeutics, Inc.33$618
Amneal Pharmaceuticals LLC28$541
Vanda Pharmaceuticals Inc.39$512
Neurelis, Inc.22$505
Avanir Pharmaceuticals, Inc.30$472
Alnylam Pharmaceuticals Inc.18$467
Takeda Pharmaceuticals U.S.A., Inc.25$418
Bristol Myers Squibb20$384
Sumitomo Pharma America, Inc.25$347
Mallinckrodt Hospital Products Inc.15$333
Biohaven Pharmaceutical Holding Company Ltd.25$315
Adamas Pharmaceuticals, Inc.21$300
Merck12$228
Tanabe Pharma America, Inc.10$221
Sunovion Pharmaceuticals Inc.2$216
Amgen10$176
Upsher-smith Laboratories LLC10$170
E.r. Squibb & Sons, L.L.C.6$163
Catalyst Pharmaceuticals, Inc.8$150
Arbor Pharmaceuticals, Inc.10$148
Biohaven Pharmaceuticals, Inc.11$130
Vertical Pharmaceuticals, LLC7$130
AstraZeneca(2 entities)6$125
SK Life Science, Inc.5$109
GE HealthCare3$95
Scilex Pharmaceuticals Inc.5$92
Avion Pharmaceuticals5$89
Acorda Therapeutics, Inc5$86
Johnson & Johnson4$85
Avadel CNS Pharmaceuticals, LLC4$84
Idorsia Pharmaceuticals US Inc5$77
Corium, LLC4$66
Ultragenyx Pharmaceutical Inc.3$52
Azurity Pharmaceuticals, Inc.2$34
Inspire Medical Systems, Inc.1$31
Collegium Pharmaceutical, Inc.2$28
Grifols USA, LLC1$26
Biomarin Pharmaceutical Inc.1$25
Novo Nordisk1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,402 in reported general payments places this provider in the 85th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$641,872
Medicare patients
350
Services billed
2,669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl53$778,514
CortrophinCorticotropin19$696,153
NuplazidPimavanserin Tartrate71$433,649
CaplytaLumateperone Tosylate175$289,421
IngrezzaValbenazine Tosylate31$234,537
Austedo XrDeutetrabenazine19$206,570
NourianzIstradefylline97$193,827
TrintellixVortioxetine Hydrobromide207$119,136
AptiomEslicarbazepine Acetate39$90,917
Nurtec OdtRimegepant Sulfate47$89,790
MounjaroTirzepatide87$88,039
RexultiBrexpiprazole40$87,327
NeuproRotigotine68$81,535
SunosiSolriamfetol Hcl56$60,893
UbrelvyUbrogepant43$58,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$1,303$778,51453 claims
Acadia Pharmaceuticals IncNuplazid$859$433,64971 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,898$289,421175 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$780$263,09471 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$2,521$206,57019 claims
Kyowa Kirin, Inc.Nourianz$973$193,82797 claims
AbbVieUbrelvy, Qulipta, Vraylar, Fetzima$4,574$156,344137 claims
UCB, Inc.Neupro, Briviact$1,398$134,271106 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$418$119,136207 claims
Sunovion Pharmaceuticals Inc.Aptiom$216$90,91739 claims
PfizerNurtec Odt$921$89,79047 claims
Lilly USA, LLCMounjaro$1,390$88,03987 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 442 neurology providers in Maryland.

Other neurology in Kensington

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →